Grant: Engage Grants Program
McGill University
$25,000.00
Development of an efficient synthetic strategy for the preparation of amine oxidase inhibitors
EF 2016-17
Résumé
Amplia Pharmatek has validated a specific form of Lysyl oxidase enzymes (LOX) as a potential therapeutictarget for fibrosis diseases. There are no advanced inhibitors for this newly-cloned enzyme although a chemicalseries has been identified. However, the effort to further develop these inhibitors has been impeded by thecomplexity of their syntheses. In this proposal, Amplia Pharmatek and the Moitessier research group willidentify improved synthetic strategies. Moitessier and his team's expertise lies in the development of efficientand green methods to prepare molecular scaffolds for medicinal chemistry applications. This expertise willcomplement that of Amplia Pharmatek and will be an asset to solve this synthetic problem. The improvedsynthetic route that will be developed through this collaboration will allow Amplia Pharmatek to furtherexplore and optimize the compounds, assess potential liabilities and further progress the lead compounds intothe development stage.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
494850-2016
Name nom
Moitessier, Nicolas
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Development of an efficient synthetic strategy for the preparation of amine oxidase inhibitors
Keyword
NSERC
Application summary
Amplia Pharmatek has validated a specific form of Lysyl oxidase enzymes (LOX) as a potential therapeutictarget for fibrosis diseases. There are no advanced inhibitors for this newly-cloned enzyme although a chemicalseries has been identified. However, the effort to further develop these inhibitors has been impeded by thecomplexity of their syntheses. In this proposal, Amplia Pharmatek and the Moitessier research group willidentify improved synthetic strategies. Moitessier and his team's expertise lies in the development of efficientand green methods to prepare molecular scaffolds for medicinal chemistry applications. This expertise willcomplement that of Amplia Pharmatek and will be an asset to solve this synthetic problem. The improvedsynthetic route that will be developed through this collaboration will allow Amplia Pharmatek to furtherexplore and optimize the compounds, assess potential liabilities and further progress the lead compounds intothe development stage.